Vikash Singh

Independent Expert @European Commission

Cambridge, GB
MOBILE NUMBERS
+91 *********19

Signup · Get unlimited contacts

WORK HISTORY

Feb 2026 — Present

Independent Expert @European Commission

View department →

EDUCATION

2006 — 2009

University of Mumbai

Bachelor of Science (B.Sc.), Biotechnology

N/A

University of Cambridge

Pathology/Experimental Pathology

N/A

Humboldt-Universität zu Berlin

Doctor of Philosophy - PhD

2025 — 2025

Cambridge Judge Business School

EnterpriseTech Programme

2010 — 2011

ETH Zürich

M.Sc, Microbiology and Immunology

2004 — 2005

Navy Children School

CBSE 12, Science

ABOUT VIKASH SINGH

I’m the Founder & CEO of CamBioLogics, where we aim to built Smart and personilised solutions for major biological issues. The 2 main areas which we are initially targeting are Cell and Gene therpay and Rare Diseases. We are re-engineering how cell and gene therapies are designed — moving the field beyond costly trial-and-error and toward predictive, data-driven development.CAR-T and CAR-NK therapies have transformed cancer care, yet too many programmes still fail early due to preventable design flaws. I founded CamBioLogics to solve that problem at its root. Our first platform, SmartCAR™, integrates patient biology, computational modelling, and construct–vector co-optimisation into a single, regulatory-ready workflow — enabling smarter decisions before capital is burned in the clinic.My focus as CEO is simple: reduce design-attributable attrition, accelerate timelines, and materially improve the probability of clinical success. We are building infrastructure, not incremental tools — technology that can become foundational to the next generation of engineered cell therapies.I combine scientific depth with strategic execution, bridging computational biology, immunotherapy, and translational development. I care deeply about rigorous thinking, capital efficiency, and building teams that execute with clarity and speed.We are actively partnering with pharma, biotech, and academic groups who want to design better therapies from day one — and engaging with investors who see the opportunity to modernise how advanced therapeutics are engineered.If you’re interested in shaping the future of programmable cell therapy, let’s talk.

This profile is compiled from publicly available professional sources. Unifers is not affiliated with or endorsed by LinkedIn. Request removal of this profile.

Vikash Singh — Independent Expert at European Commission in Cambridge, GB | Unifers